

**Original article**

**CONSCIOUS SEDATION WITH DEXMEDETOMIDIINE/ MIDAZOLAM INFUSION IN PATIENTS WITH INYRATHECAL BUPIVACAINE FOR INFRAUMBILICAL SURGERIES.**

**Dr.Devanshi Shah(Resident in Anesthesia, Dr.Manisha kapdi(Associate professor in Anaesthesia,V S General Hospital and NHL medical college Ahmedabad pin 380006**

**Corresponding author: Dr. Manisha kapdi:manisha\_kapdi@yahoo.com**

**Key words: CONSCIOUS SEDATION ,DEXMEDETOMIDIINE/ MIDAZOLAM INFUSION ,INFRAUMBILICAL SURGERIES.**

**ABSTRACT**

**Background:** *spinal anesthesia is very much common regional anesthesia. Assurance and conscious sedation is required to make patients calm and co-operative. We have also assessed effect of dexmedetomidine/ midazolam infusion on sensorimotor characteristics of spinal bupivacaine.*

**Material and methods :**

*We selected 50patients for the study, 25 in each group.*

**Group-D :** *Received a loading dose of I.V dexmedetomidine 0.5mcg/kg by infusion pump over 10 min + 0.5mcg/kg/hr infusion till the end of surgery.*

**Group-M :** *Recieved a loading dose of I.V midazolam 0.02mg/kg by infusion pump over 10 min + 0.04mg/kg/hr infusion till the end of surgery. **Observation** The pulse rate & SBP in group D was significantly lower as compared to group M from 10 minutes to 120 minutes after subarachnoid block. Significant difference was seen between group D and group M. There was no statistically significant change in pulse rate between 120mins to 24 hrs postoperatively between the groups.*

*There was no statistically significant difference up to 24 hrs post operatively.*

*There was no significant change in RR and SPO<sub>2</sub> in any group.*

*Highest sensory level and duration of sensory and motor blockade and duration of analgesia and No. Of analgesic requests in 24 hrs were compared.*

*Intraoperative and postoperative adverse effects were noted.*

*Higher sensory level (T<sub>5</sub> 28% and T<sub>6</sub> 72%) is achieved in Group D as compared to Group M ( T<sub>6</sub> 44% and T<sub>8</sub> 56%). Time to regression by two dermatome (min) in group D is 211 ±11.4 where as in group M is 162±11.3 which is highly significant ( p < 0.001 ). Time of 1<sup>st</sup> rescue analgesic (min) in group D is 325 ± 23.7 where as in group M is 218 ± 15.3 which is highly significant ( p < 0.001 ). Time of motor block to Bromage 1 (min) in group D is 246 ± 16.5 where as in group M is 236 ± 16.6 which is statistically significant ( p < 0.05). Analgesic requests in 24 hrs (no.) in group D is 1.96 ± 0.35 where as in group M is 3.4 ± 0.50 which is highly significant ( p < 0.001 ). In group D hypotension occurred in 2 (8%) patients and bradycardia in 5 (20%) patients. No other adverse effect noticed in group D. In group M respiratory depression occurred in 4 (16%) patients and shivering in 2 (8%) patients.*  
**Conclusion:** *DEXMEDETOMIDINE is more effective supplementation than Midazolam in terms of sedation as well as prolonged sensorimotor characteristics of intrathecal bupivacaine.*

**Key words: conscious Sedation, dexmedetomidine infusion, midazolam infusion, intrathecal bupivacaine.**

## **INTRODUCTION**

Multimodal anesthesia techniques are available for infraumbilical and lower limb surgeries e.g- regional anesthesia (spinal, epidural), local anesthesia, peripheral block, general anesthesia. Subarachnoid block is popular among them.

Bupivacaine is the most commonly used local anaesthetic agent having satisfactory sensory and motor blockade with limited duration of action. Various intrathecal adjuvant have been tried with local anaesthetic agents

“Pain” is an unpleasant sensory and emotional experience associated with actual / potential tissue damage or described in terms of such tissue damage.<sup>11</sup> Many factors modify pain.

Concept of post operative analgesia is gaining importance now-a-days. So the aim of anesthesia technique should be;- minimum invasive, causes minimum adverse effect, provide prolonged analgesia and economically acceptable.

**CONSCIOUS SEDATION** only some of the centers in the medullary reticular formation and thalamus are depressed in a dose dependent manner. Thus this level of sedation additionally provides the benefit of preservation of protective airway reflexes, especially in monitored anesthesia care.<sup>19</sup>

Dexmedetomidine a parenteral selective  $\alpha_2$  agonist<sup>39</sup> with sedative anxiolytic and analgesic properties without causing respiratory depression. The sedative and analgesic effects are mediated by  $\alpha_2$  adrenergic receptors in the brain(Locus ceruleus)<sup>15</sup> and spinal cord. So it provides adequate sedation after spinal anesthesia, reduces anxiety level, physiological and psychological stress and patient and surgeon satisfaction. It also alleviates position related discomfort. Most importantly it has an opioid sparing effect so does not significantly depresses respiratory drive. Few studies suggest that I.V dexmedetomidine supplementation prolongs the effect of spinal anesthesia.<sup>18</sup> Dexmedetomidine has unique pharmacodynamic properties it is suitable for peri-operative care during general and regional anesthesia. It is used as adjuvant to regional anesthesia.<sup>14</sup>

Midazolam is a water soluble short acting benzodiazepine which is used for pre-operative medication and conscious sedation. The amnestic effect of midazolam is more potent than its analgesic effect. Thus patients may be awake following administration of midazolam but remains amnestic for events and conversations for several hours.<sup>27,28,29</sup>

The present study was undertaken to evaluate efficacy and potency of midazolam and dexmedetomidine infusion administered intra-venously just after induction with intra thecal bupivacaine for effect on sensory and motor blockade, sedation hemodynamic stability, duration

of effective analgesia, post-operative pain relief, post-operative analgesic requirement and adverse effect of drugs used.

### **AIMS OF STUDY**

present study was designed to compare the effect of intravenous dexmedetomidine (Group-D), intravenous midazolam (Group-M) administered just after giving spinal anesthesia with 3.0 ml bupivacaine in various infraumbilical and lower limb surgeries for the following points:- To evaluate the efficacy of I.V dexmedetomidine and I.V midazolam on subarachnoid block by intrathecal bupivacaine., To evaluate the effect of both I.V drugs on sensory and motor blockage, To observe intraoperative and postoperative hemodynamic stability in both the groups, To observe intraoperative and postoperative sedation, Duration of effective analgesia, To observe any perioperative adverse effect, Duration of postoperative analgesia.

### **MATERIAL AND METHODS**

A randomized controlled study was conducted on 50 patients (ASA grade I or II) aged 20-60 years scheduled for infra-umbilical surgeries after taking informed consent.

#### **Study Protocol:-**

Detailed preoperative history and physical examination of patient done. Patients having h/o allergy to any study drug and contraindications for spinal anesthesia are excluded from study. All the patients were evaluated pre-operatively and laboratory investigations complete blood count, blood sugar, renal function tests, serum bilirubin, serum electrolytes and chest x-ray, ECG were reviewed.

Procedure was explained to patient. Patient was informed about perception of pain and perception of any discomfort during surgery. VAS score was explained to the patient on 1-10 scale.

Written informed consent of patient and their relative taken.

#### **EXCLUSION CRITERIA :**

Patient's age less than 20 years and above 60 years, Pregnant patients,

Infection at site of block, History of allergy to local anaesthesia drug, Patient with severe cardiac or respiratory disease, Patient with coagulation disorder, Patients who were selected and posted for surgeries were randomly allocated in two groups.

Group-D : Received a loading dose of I.V dexmedetomidine 0.5mcg/kg by infusion pump over 10 min + 0.5mcg/kg/hr infusion till the end of surgery.

Group-M : Received a loading dose of I.V midazolam 0.02mg/kg by infusion pump over 10 min + 0.04mg/kg/hr infusion till the end of surgery.

## **PREPARATION**

All the patients were fasted for minimum 6 hours prior to scheduled time of surgery. Psychological preparation was done and the procedure explained to all the patients in advance.

On arrival in the operating room an I.V. access was secured using an 18G cannula. Each patient preloaded with infusion of 10 to 15 ml/kg of lactated Ringer's solution. Standard monitoring included continuous electro-cardiogram, pulse-oximetry, non-invasive blood pressure measurements and visual assessment of respiration. Inj. Ondansatrone 0.08 mg/kg iv and inj. Glycopyrolate 0.004mg/kg I.M given as premedication 30 min before dura puncture.

## **PROCEDURE**

In all the patients, under strict aseptic and antiseptic precautions, lumbar puncture was performed (after giving local anaesthesia with a 26G hypodermic needle) using a 25-gauge Quincke's needle positioned midline at the L3-L4 interspace in lateral position.

Patients of both the group received 3 ml (15 mg) hyperbaric bupivacaine 0.5% in subarachnoid block. After completion of injections the patients were immediately returned to the supine position, pillow was placed under head of the patient and time of injection was noted. Then afterwards no change in patient's position done.<sup>9,25</sup> Just after giving supine position patients of group D received a loading dose of I.V dexmedetomidine 0.5mcg/kg by infusion pump over 10 min + 0.5mcg/kg/hr infusion till the end of surgery and group M patients received a loading dose of I.V midazolam 0.02mg/kg by infusion pump over 10 min + 0.04mg/kg/hr infusion till the end of surgery.

Sensory block was assessed by the loss of sensation to pinprick. Time to onset of sensory block, maximum level of sensory block achieved and time to achieve maximum sensory block were noted in minutes. Sensory level in between T<sub>5</sub> - T<sub>8</sub> was achieved. Time from subarachnoid injection to second sacral dermatome (S<sub>2</sub>) was assessed by pinprick and recorded in minutes.

Motor block was assessed by Modified Bromage score.

Time for onset of grade-3 motor blockade was noted.

Total duration of grade-3 motor blockade was noted.

## **DATA COLLECTION**

Pulse, BP, SPO<sub>2</sub> and RR were recorded on 1, 5, 10, 20, 30, 45, 60, 90 and 120 minutes after giving spinal anaesthesia.

## **INTRA OPERATIVE ADVERSE EFFECTS:-**

Patients of both the group are observed for adverse effects like,

Sedation, Hypotension, Bradycardia, Respiratory depression

Nausea, Vomiting, shivering, Dryness of mouth, Involuntary (paradoxical) movements<sup>40</sup>. Sedation levels were assessed using Ramsay's sedation score.

Hypotension (defined as 30% fall in systolic BP from the baseline systolic BP) was treated with intravenous fluids and inj. Mephentermine 6 mg i.v. Bradycardia (defined as pulse rate < 60 beats per minute) was treated with inj. Atropine 0.6 mg i.v. Shivering was treated with 100% O<sub>2</sub> warm fluids and adequate patient covering.<sup>7</sup> No other sedative or analgesic drug was given to the patients intraoperatively. Respiratory depression (defined as RR < 12 / min or SPO<sub>2</sub> < 90%) was treated with 100% O<sub>2</sub>. In addition to the loading dose of intravenous fluids, patients received a maintenance infusion of lactated ringer's solution as calculated according to the conventional formula.

Shivering, nausea, vomiting if present treated accordingly.

Duration of surgery for each case was noted.

After completion of surgery patients are monitored every 30 min upto 2 hrs then at 4 hrs, 6 hrs, 12hrs and 24hrs.

Pain measurement was done using VAS scale.

When VAS score was >3 cm, the patients were given inj. Tramadol 1 mg/kg I.V + inj. Ondansatrone 0.08 mg/kg I.V and 'Time to first rescue analgesic' recorded in minutes Patients were inquired about neurological deficit 7 days post-operatively.

## STATISTICAL ANALYSIS

Statistical analysis done using the SPSS software. Inter-group comparison was done, using paired 't' test as well as comparing mean and standard deviation. A 'p' value < 0.05 was taken as significant an 'p' value < 0.001 was taken as highly significant.

## OBSERVATIONSAND RESULTS

The present study was undertaken to evaluate efficacy and potency of midazolam and dexmeditomedine administered intra-venously just after induction with intra thecal bupivacaine for effect on sensory and motor blockade, sedation hemodynamic stability, duration of effective analgesia, post-operative pain relief, post-operative analgesic requierment and adverse effect of drugs used. We have evaluated 50 patients randomly divided in two groups of 25 each.

**Table 1.**

<b>DEMOGRAPHIC CHARACTERISTICS</b>			
	<b>Group D</b>	<b>Group M</b>	<b>Inference</b>
<b>Sex(M/F)</b>	15/10	13/12	NS

Age(Years)	46.08±5.90	43.48±5.77	NS
Height(cm)	164.6±6.034	164.04±5.74	NS
Weight(kg)	66.84±4.50	65.72±4.83	NS
ASA I/II	13/12	12/13	NS
Duration of surgery (min)	95.4± 12.83	98.0 ± 10.21	NS

Demographically both groups are comparable. There was no significant difference between them Haemodynamics;

There was significant difference in HR 5 min after administration of the study drugs. In group D ,HR and SBP remain 20% less than baseline from 10 to 120 min in comparison to Group M(P<0.001)There was no change in haemodynamics in Postoperative period

RSS score:

Mean RSS of the D group was 3.4 whereas of M group was 5.4 after 15 mins.(p<0.001)

**Table 2**

<b>CHARACTERISTICS OF SPINAL BLOCK</b>				
	Group D	Group M	P-Value	Inference
Time to regression by 2 dermatome (min)	211 ± 11.4	162 ± 11.3	< 0.001	HS
Time of 1 <sup>st</sup> rescue analgesic (min)	325 ± 23.7	218 ± 15.3	< 0.001	HS
Time of motor block to	246 ± 16.5	236 ± 16.6	0.03	S

Bromage 1(min)				
Analgesic requests in 24 hrs (no.)	1.96 ± 0.35	3.4 ± 0.50	< 0.001	HS

Table 2 shows characteristics of spinal block in the two groups. Statistically highly significant difference was present between the two groups for time to regression by 2 dermatome, time of 1<sup>st</sup> rescue analgesic and analgesic requests in 24 hrs (no.).

Highest sensory level:

Significantly higher sensory level is achieved in Group D 72% patients have T6 level, In group M 44% patients have T6 level.

Adverse effects:

In group D 6 patients have bradycardia & 2 have Hypotension, In group M 4 patients have Respiratory depression, 2 patients have shivering, like various adverse effects .

### **Postoperative Monitoring :**

We have monitored all patients in post-operative period till 24 hrs for HR, B.P, SpO<sub>2</sub> , RR, RSS and VAS every 30 mins till 2 hrs then at 4 hrs, 6 hrs, 12 hrs and 24 hr Post operative Vital parameters of All patients were in normal limits.

Analgesics were repeated after VAS was more than 3.

All patients were conscious and co-operative.

No adverse effect noted during post-operative monitoring

### **Discussion**

Spinal anaesthesia is the preferred anaesthesia technique for lower abdominal and lower limb surgeries. Bupivacaine is the most commonly used local anaesthetic in spinal anaesthesia. The use of adjuvants with local anaesthetics provides prolonged and superior quality of anaesthesia and postoperative analgesia with relatively small doses of individual drugs with less requirement of postoperative analgesia. Duration of analgesic

action of local anaesthetics can be prolonged by mixing them with certain pharmacologic agents called additives or adjuvants. A wide variety of centrally active drugs are used to provide sedation, anxiolysis and amnesia. Dexmedetomidine is an attractive alternative to anesthetic adjuvant used at present due to its anesthetic sparing and hemodynamic stabilizing effects. Used along with regional anesthesia, dexmedetomidine prolongs the action of local anesthetics along with providing analgesia and sedation without causing respiratory depression. Dexmedetomidine is also used as a sedative for monitored anesthesia care due to its analgesic properties, co-operative sedation and lack of respiratory depression.<sup>36</sup>

Current literatures suggest a ceiling effect on prolonging post-spinal analgesia after 0.5 mg /kg boluses. With increasing the dose beyond 0.5 mg /kg resulted in unwanted side effects notably bradycardia and excessive sedation. Dexmedetomidine has linear pharmacokinetics and dose dependent sedative action, when a loading dose of dexmedetomidine 1 mcg/kg administered over 10 min, the average peak concentration was reached in 17 min with terminal half-life of 2 hr 10 min. So a single bolus dose might be sufficient for procedure lasting less than 60 min whereas continuous infusion is needed for longer procedure.

## **DEMOGRAPHIC CHARACTERISTICS :**

Table 1 shows demographic characteristics of both the groups. The two groups were comparable ( $p > 0.05$ ).

In 2015 **Surjya Prasad Upadyay et al<sup>37</sup>**, study shows same comparable demographics

### **Heamodynamic characteristics :**

**Heart rate :**HR ( bpm) variation in two study group. Base line ( grp. D  $99.3 \pm 6.52$ , grp M  $99.3 \pm 6.92$ ) and 1 min (grp D  $99.0 \pm 4.68$ , grp M  $98.6 \pm 6.88$ ) values in both the group are comparable and statistically not significant (  $p > 0.05$ ). After 5 mins in Group D and as compared to Group M fall in HR is statistically highly significant (  $p < 0.001$ ).

Lower heart rate in Group D can be explained due to decreased sympathetic outflow by activation of post-synaptic  $\alpha_2$  receptors in CNS and decreased circulatory levels of catecholamines caused by dexmedetomidine.

In 2014 **Swati Bist et al**<sup>38</sup>, observed that the reduction in heart rate was more in group D than in group M, 5 mins afterwards starting dexmedetomidine infusion.

In 2011 **Yongxin et al**<sup>41</sup>, observed that the Dexmedetomidine patients in this study had a significant reduction in HR which occurred most commonly during a bolus or within 10 minutes of the start of an infusion.

In 2014 **Chilkunda et al**<sup>8</sup>, observed significantly higher proportion of patients in the dexmedetomidine group (33%) had bradycardia compared to the control group (4%).

### **Systolic Blood Pressure :**

**Variation** in systolic blood pressure amongst the two groups. There is no statistically significant difference in SBP of the two groups at base-line, one min and at 5 min. 10 min onwards there is a highly significant difference in SBP in the two groups.

**Swati Bist et al 38** observed that Group D recorded a significant fall in systolic blood pressure (SBP) after 40 minutes ( $p < 0.006$ ). **Chilkunda et al**<sup>8</sup>, conducted a study in which. They observed significantly higher proportion of patients in group D had bradycardia and fall in systolic blood pressure more than 20% of baseline value. Systolic, diastolic, and mean arterial blood pressures were relatively lower in group D.

In 2011 **Yongxin et al**<sup>4</sup> observed that MAP was significantly reduced during the intraoperative period in two groups, and the reduction did not show significant differences between the two groups.

**Ramssay's sedation score** intra-operative RSS in the two study groups. The highest level of sedation achieved in the two groups are significantly different. Intraoperative Ramsay sedation scores were significantly higher in group D (range 2-4) as compared to group M (range 2-6); ( $P < 0.001$ ). Maximum scores in group D ranged from 3 to 4. In group D, the maximum sedation score was 4 whereas in group M maximum sedation score was 6. RSS of Post-operative period in both groups were comparable with no significant difference.

**Kaya.F.N et al**<sup>20</sup>, observed that the median (range) of the highest Ramsay sedation score was 2 (2-5) in the dexmedetomidine group, 3 (2-5) in the midazolam group ( $P < 0.001$ ). Excessive

sedation (Ramsay sedation score of 5) was observed in two patients of the dexmedetomidine group and in five patients of the midazolam group.

**Sang Hi Park et al<sup>35</sup>**, observed that there was no patient who showed excessive sedation in the control group. To show excessive sedation means Ramsay sedation score = 5 or 6). In the dexmedetomidine 0.5 Group and 1.0 group RSS was significantly higher than control group . In both Dexmedetomidine groups, sedation score was the deepest around the 20-minute period and it decreased thereafter .

**Chilkunda et al<sup>8</sup>**, observed that intraoperative Ramsay sedation scores were significantly higher in group D (mean  $4.4 \pm 0.7$ , range 3-6) as compared to group C (mean  $2 \pm 0.1$ , range 2-3) ( $P < 0.001$ )

#### **CHARACTERISTICS OF SPINAL BLOCK :**

Table 4 shows effect of the study drugs on different characteristics of spinal block. Time to regression by two dermatome (min) in group D is  $211 \pm 11.4$  where as in group M is  $162 \pm 11.3$  which is highly significant ( $p < 0.001$ ) Time of 1<sup>st</sup> rescue analgesic (min) in group D is  $325 \pm 23.7$  where as in group M is  $218 \pm 15.3$  which is highly significant ( $p < 0.001$ ). Time of motor block to Bromage 1 (min) in group D is  $246 \pm 16.5$  where as in group M is  $236 \pm 16.6$  which is statistically significant ( $p < 0.05$ ). Analgesic requests in 24 hrs (no.) in group D is  $1.96 \pm 0.35$  where as in group M is  $3.4 \pm 0.50$  which is highly significant ( $p < 0.001$ ).

**Swati Bist et al<sup>38</sup>**, show that better sensorimotor characteristics with Dexmedetomidine group than Midazolam group P value  $< 0.001$ .

In **2015 Kiran Kumar S et al (22)** observed that the Duration for 2 dermatomal Regression of sensory blockade ( $137.4 \pm 10.9$  mins), duration of sensory blockade ( $269.8 \pm 20.7$  min) and duration for motor block regression to Modified Bromage scale 0 ( $220.7 \pm 16.5$  mins) prolonged significantly than clonidine and control groups.

In **2014 Ahmed et al<sup>2</sup>**, observed that dexmedetomidine intravenously or intrathecally extended the duration of bupivacaine motor block and it was significantly longer in the IT group compared with the IV group.

**Kaya.F.N et al<sup>20</sup>**, observed that the time for sensory regression of two dermatomes was  $145 \pm 26$  min in the dexmedetomidine group, than in the midazolam ( $P < 0.05$ ) and saline ( $P < 0.05$ ) groups. **Reddy et al<sup>32</sup>**, Conducted a study and observed better spinal characteristics in Dexmedetomidine group than clonidine and placebo groups.

**Highest sensory level achieved** : Table 6 shows highest sensory level achieved in the both study groups. Higher sensory level ( $T_5$  28% and  $T_6$  72% ) is achieved in Group D as compared to Group M (  $T_6$  44% and  $T_8$  56%).our results correlate with results of Swati **Bist et al<sup>38</sup>**, **Kaya.F.N et al (20)**, **Reddy et al** (  $p < 0.001$  ).

**Adverse effects** ( in no. of patients ) in the two different groups. In group D hypotension occurred in 2 (8%) patients and bradycardia in 5 (20%) patients. No other adverse effect noticed in group D. In group M respiratory depression occurred in 4 (16%) patients and shivering in 2 (8%) patients. Adverse effect profile in different groups are related to pharmacological properties of the study drugs.

In 2011 **Yongxin et al<sup>41</sup>**, and they observed that the patients who had received dexmedetomidine for sedation during the surgical procedure had no respiratory depression but in midazolam group total 8 patients had respiratory depression. The number of patients who suffered bradycardia was significantly larger in the dexmedetomidine group.

In 2014 **Chilkunda et al<sup>8</sup>**, conducted a study in which there was no shivering in groupD but present in control group (10%).

### **Conclusion:**

**DEXMEDETOMIDINE** markedly prolongs duration of sensory blockage, arousable sedation and provides excellent quality of post-operative analgesia with decreases no. of analgesic requests in 24 hrs. But it should be used cautiously due to its hemodynamic effects.

**MIDAZOLAM** provides stable hemodynamics with higher level of sedation but comparatively less effect on quality of spinal blockage and post-operative analgesia.

### **REFERENCES:**

- (1) Aho M, Erkola O, Kallio A, Scheinin H, Korttila K. Comparison of dexmedetomidine and midazolam sedation and antagonism of dexmedetomidine with atipamezole. *J Clin Anesth.* 1993; 5: 194-203.
- (2) Ahmed M.S., Talaat SM. Effect of intravenous versus intrathecal low-dose dexmedetomidine on spinal block in lower limb orthopedic surgery. *Ain-Shams J Anaesthesiol* 2014; 7: 205-210.
- (3) Al-Mustafa MM, Badran IZ, Abu-Ali HM, Al-Barazangi, Massad IM, Al-Ghanem SM., Intravenous Dexmedetomidine prolongs bupivacaine spinal analgesia. *Middle East Journal of Anesthesiology.* 2009 Jun20;(2):225-31.
- (4) Andrés J, Gil A, Bolinches R Predictors of patient satisfaction with regional anesthesia. *Reg anesth* 5 Nov-Dec;20(6):498-505.
- (5) Bajwa SJ, Gupta S, Kaur J, Singh A, Parmar S. Reduction in the incidence of shivering with perioperative dexmedetomidine: A randomized prospective study. *J Anaesthesiol Clin Pharmacol.* 2012; 28: 86-91.
- (6) Bergese SD, Patrick Bender S, McSweeney TD, Fernandez S, Dzwonczyk R, Sage K., A comparative study of Dexmedetomidine and midazolam alone for sedation during elective awake fiberoptic intubation. *Journal of Clinical Anesthesia.* 2010 Feb;22(1):35-40.
- (7) Bhattacharya P, Bhattacharya L. Post anaesthesia shivering (PAS): A review. *Indian J Anaesth* 2003; 47: 88-93.
- (8) Chilkunda N Dinesh, Sai Tej NA, Yatish B, Pujari VS, Mohan Kumar RM, Mohan CV. Effects of intravenous dexmedetomidine on hyperbaric bupivacaine spinal anesthesia: A randomized study. *Saudi J Anaesth.* 2014; 8: 202-208.

- (9) Collins: Principles of anaesthesiology; 3<sup>rd</sup> edition, 1993, pg no. 893.
- (10) Collins: Principles of anaesthesiology; 3<sup>rd</sup> edition, volume 2,1993, pg no.- 1466-1478.
- (11) Edward Morgan Jr. G., Maged S. Mikhail, Michael J. Murray. Clinical anaesthesiology, 4<sup>th</sup> edition, Chapter -18, pg no. 361.
- (12) Eren G, Gukurova Z, Demir G, Hergunsel O, Kozanhan B, Emir NS., Comparison of Dexmedetomidine and three different doses of midazolam in preoperative sedation. Journal of Anaesthesiology Clinical Pharmacology; Jul-Sep 2011;27(3).367-72.
- (13) Faull RL, Villiger JW. Benzodiazepine receptors in the human spinal cord: a detailed anatomical and pharmacological study. Neuroscience 1986;17:791-802.
- (14) Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexmedetomidine: a novel sedative analgesic agent., Baylor University Medical Center proceeding Jan 2001;14:13-21.
- (15) Guo TZ, Jiang JY, Buttermann AE, Maze M. Dexmedetomidine injection into the locus ceruleus produces antinociception. Anesthesiology. 1996; 84: 873-881.
- (16) Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000; 90: 699-705.
- (17) Harsoor S, Rani DD, Yalamuru B, Sudheesh K, Nethra S. Effect of supplementation of low dose intravenous dexmedetomidine on characteristics of spinal anaesthesia with hyperbaric bupivacaine. Indian J Anaesth. 2013; 57: 265-269.
- (18) Jaakola ML, Salonen M, Lehtinen R, Scheinin H. The analgesic action of dexmedetomidine--a novel alpha 2-adrenoceptor agonist--in healthy volunteers. Pain. 1991; 46: 281-285.29.
- (19) Jyotsna Pravin Bhosale, Dr. Ozair Noor Trumboo, Dr. S.S. Aphale Comparison Of Propofol And Midazolam Infusion For Conscious Sedation During Spinal Anaesthesia :

*Quest Journals Journal of Medical and Dental Science Research Volume 2~ Issue 1 (2015) pp: 19-24.*

- (20) Kaya FN, Yavascaoglu B, Turker G, Yildirim A, Gurbet A, Mogol EB, et al. Intravenous dexmedetomidine, but not midazolam, prolongs bupivacaine spinal anesthesia. *Can J Anaesth.* 2010; 57: 39-45. 30.
- (21) Keith A, Sergin D, Paula M, Marc A, Wisemandle W, Alex Y. Monitored anesthesia care with dexmedetomidine: A prospective, randomized, double blind, multicenter trial. *Anesth Analog* 2010; 110: 47-56.
- (22) Kiran Kumar S. and Kishan Rao B. A comparative study on efficacy of intravenous dexmedetomidine vs intravenous clonidine to prolong bupivacaine spinal anaesthesia : *International Journal of Basic and Applied Medical Sciences ISSN: 2277-2103 , 2015 Vol. 5 (2) May-August, pp. 274-279.*
- (23) Spencer S MD; Wu, Christopher L. MD The Effect of Analgesic Technique on Postoperative Patient-Reported Outcomes Including Analgesia: A Systematic Review : *Anesthesia & Analgesia* September 2007 vol. 105, Issue – 3. pp 789-808.
- (24) *Miller's anaesthesia 7<sup>th</sup> edition, chapter 26, pg no. 751- 756.*
- (25) *Miller's anaesthesia; 6<sup>th</sup> edition, 2005, pg no. 634-636.*
- (26) Neal JM. Hypotension and bradycardia during spinal anesthesia: Significance, prevention, and treatment. *Techniques in Regional Anesthesia and Pain Management* 2000;4:148-154.
- (27) Nishiyama T, Hirasaki A, Odaka Y, Iwasaki T, Seto K. Midazolam sedation during spinal anesthesia: Optimal dosage. *J Jpn Soc Clin Anesth* 1994;14:257-62.
- (28) Nishiyama T, Hanaoka K. The necessity and the efficacy of the second administration of midazolam for sedation during spinal anesthesia. *Masui* 2000;49:245-49.

- (29) Nishiyama T, Hirasaki A, Odaka Y, Iwasaki T, Seto K. Midazolam sedation during spinal anesthesia: Optimal dosage. *J Jpn Soc Clin Anesth* 1994;14:257-62.
- (30) Niv D, Davidovich S, Gelter E, Urca G. Analgesic and hyperalgesic effects of midazolam; dependence on route of administration. *Anesth Analg* 1988; 67:1169-73.
- (31) Philipp M, Brede M, Hein L. Physiological significance of alpha (2)-adrenergic receptor subtype diversity: one receptor is not enough. *Am J Physiol Regul Integr Comp Physiol*. 2002; 283: R287-295.
- (32) Reddy VS, Shaik NA, Donthu B, Sannala VK, Jangam V. Intravenous dexmedetomidine versus clonidine for prolongation of bupivacaine spinal anesthesia and analgesia: A randomized double-blind study. *J Anaesthesiol Clin Pharmacol* 2013; 29: 342-347.
- (33) Reihanak Talakoub; Mehran Rezvani; Ameneh Alikhani ; Mohammad Golparvar ; Mitra Jabalameli ; Zahra Amini : The Effect of Intravenous Midazolam on Duration of Spinal Anesthesia, *Shiraz E-Med J*. 2015 April; 16(4): e21586.
- (34) Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and use in anesthesiology. *985;62:310-24*.
- (35) Sang Hi Park, Young Duck Shin, Hyun Jeong Yu, Jin Ho Bae, and Kyoung Hoon Yim : Comparison of two dosing schedules of intravenous dexmedetomidine in elderly patients during spinal anesthesia. *Korean J Anesthesiol* 2014 May 66(5): 371-376.
- (36) Sudheesh K, Harsoor S. Dexmedetomidine in anaesthesia practice: A wonder drug? *Indian J Anaesth*. 2011; 55: 323-324.
- (37) Surjya P Upadhyay , Samanth U, Tellicherry S, Mallick P (2015) Intravenous Dexmedetomidine on Quality of Spinal Block and Duration of Postoperative Analgesia - A Systemic Review and Update. *Int J Clin Anesthesiol* 3(1): 1045.

- (38) Swati Bisht, Sudha Prasad. Intravenous Dexmedetomidine Prolongs Bupivacaine Spinal Anesthesia. *Journal of Evolution of Medical and Dental Sciences*. 2014; 3: 1745-1752.
- (39) Virtanen R, Savola JM, Saano V, Nyman L. Characterisation of selectivity, specificity and potency of medetomidine as an  $\alpha$  2 receptor agonist. *Eur J Pharmacol* 1988; 150:9-11.
- (40) Weinbroumm A, Szold O, Ogorek d, Flaishon R. The midazolam induced paradox phenomenon is reversible by flumazenil. Epidemiology, patient characteristics and review of literature. *Eur J Anaesthesiol* 2001; 18: 780-97.
- (41) Yongxin Lianga, b, Miaoning Gub, Shiduan Wanga, Haichen Chua, c : A Comparison of Dexmedetomidine and Midazolam for Sedation in Gynecologic Surgery Under Epidural Anesthesia. *J Curr Surg*. 2011;1(1):12-18.